期刊
DIGESTIVE DISEASES AND SCIENCES
卷 56, 期 12, 页码 3463-3470出版社
SPRINGER
DOI: 10.1007/s10620-011-1877-6
关键词
5-aminosalicylic acid; Mesalazine; Mesalamine; Persistency; Ulcerative colitis; Pharmacy database
资金
- Shire Pharmaceuticals Inc., USA
Background Patients receiving 5-aminosalicylic acid (5-ASA) require long-term therapy to achieve good outcomes. Persistency (duration of time from initiation to discontinuation of therapy) is therefore an important consideration. Aim To evaluate persistency in patients receiving various oral 5-ASA formulations. Methods This retrospective, 12-month, cohort study examined new-starter patients (any age and diagnosis) from a large United States pharmacy database who filled a prescription for oral 5-ASA [Lialda(A (R)), Asacol(A (R)), Pentasa(A (R)) 250 or 500 mg, balsalazide (generic and Colazal(A (R))), and olsalazine (Dipentum(A (R)))] between March and September 2007. Persistency was evaluated monthly on the basis of prescription refill rates. Results Prescription and refill records were identified for 44,191 patients receiving oral 5-ASA. After 1 year, 20% of patients receiving Lialda were considered persistent and classified as continuing (refilling within a timeframe of up to twice the duration of the prescription), compared with 9% receiving Asacol, 7 (250 mg) and 10% (500 mg) receiving Pentasa, 10% receiving balsalazide, and 10% receiving Dipentum. Conclusions Overall persistency with oral 5-ASA therapy was low. However, patients receiving once-daily Lialda had significantly higher persistency after 1 year of treatment than patients receiving other oral 5-ASA therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据